Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CyMVectin
- Development stage
- Discontinued
- Lead developer
- Vical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
CyMVectin is a prophylactic DNA vaccine candidate designed to prevent congenital cytomegalovirus (CMV) infection. It utilizes a novel lipid-based adjuvant platform called Vaxfectin, which enhances the immunogenicity of DNA-based vaccines. The vaccine was developed by Vical Incorporated and is part of their pipeline focused on infectious diseases, specifically targeting the prevention of CMV transmission from mother to fetus. The mechanism involves delivering CMV antigens via plasmid DNA formulated with the Vaxfectin adjuvant to stimulate an immune response against CMV[6][9].
- Brand names
- CyMVectin
- Other names
- CyMVectin
Beyond the preview
Go deeper on CyMVectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CyMVectin.